{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45","value":"1619"},{"groupId":"OG001","spread":"21","value":"1462"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35","value":"1289"},{"groupId":"OG001","spread":"32","value":"1500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 1 Day 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84","value":"693.5"},{"groupId":"OG001","spread":"13","value":"960.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Cmax was directly observed from data. Cmax was defined as maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PF-06952229 was administered at a dose of 250 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally once a day (QD) as continuous daily dosing.","id":"OG000","title":"Part 1B: PF-06952229 250mg + Enzalutamide"},{"description":"PF-06952229 was administered at a dose of 375 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally QD as continuous daily dosing.","id":"OG001","title":"Part 1B: PF-06952229 375mg + Enzalutamide"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants with metastatic castration-resistant prostate cancer (mCRPC), conducted dose escalation of PF-06952229 in combination with enzalutamide, who had sufficient information to estimate at least 1 of the PK parameters of interest. Here, \"number analyzed\" signifies participant evaluable for each row","reportingStatus":"POSTED","timeFrame":"0 (pre dose), 0.5, 1, 2, 4, 6 and 12 hours (post dose) on Day 1 and 21 of cycle 1, 0 (pre dose), 0.5, 1, 2, 4, 6 and 12 hours (post dose) on Day 1 of cycle 2.","title":"Maximum Observed Plasma Concentration (Cmax) of PF-06952229 (Part 1B)","type":"SECONDARY","unitOfMeasure":"ng/mL"}